Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of targeted therapies for Parkinson's disease and related synucleinopathies.

Journal of lipid research - 1 Oct 2014

Sybertz Edmund, Krainc Dimitri

Abstract excerpt

Therapeutic efforts in neurodegenerative diseases have been very challenging, particularly due to a lack of validated and mechanism-based therapeutic targets and biomarkers. The basic idea underlying the novel therapeutic approaches reviewed here is that by exploring the molecular basis of neurodegeneration in a rare lysosomal disease such as Gaucher's disease (GD), new molecular targets will be identified for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Synuclein
Share to Child
Share to Child, Preschool

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gaucher Disease

Share to Glucosylceramidase

Share to Glycolipids

Share to Lipid Metabolism

Share to Parkinson Disease

Source

Open in PubMed Open full text

Identifiers

PMID: 24668939
DOI: 10.1194/jlr.R047381
PMCID: PMC4173992

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of targeted therapies for Parkinson's disease and related synucleinopathies.PMID 24668939Read ↗

Glucocerebrosidase as a therapeutic target for Parkinson's disease.Semantic proximity Read ↗

Gaucher-related synucleinopathies: the examination of sporadic neurodegeneration from a rare (disease) angle.Semantic proximity Read ↗

Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease.Semantic proximity Read ↗

Pathological Protein Targets in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapies.Semantic proximity Read ↗

Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson’s Disease: Pathogenesis and Therapeutic ImplicationsSemantic proximity Read ↗

Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicineSemantic proximity Read ↗

Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments.Semantic proximity Read ↗

GBA Variants and Parkinson Disease: Mechanisms and Treatments.Semantic proximity Read ↗

A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.Semantic proximity Read ↗

Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.Semantic proximity Read ↗

Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models.Semantic proximity Read ↗

The role of glucocerebrosidase in Parkinson disease pathogenesis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.